Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
Paul E. Harris, Trevor Brasel, Christopher Massey, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 520-520
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Antonio Bertoletti, Nina Le Bert, Anthony T. Tan
Immunity (2022) Vol. 55, Iss. 10, pp. 1764-1778
Open Access | Times Cited: 92
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
Grigoris D. Amoutzias, Marios Nikolaidis, Eleni Tryfonopoulou, et al.
Viruses (2022) Vol. 14, Iss. 1, pp. 78-78
Open Access | Times Cited: 82
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100793-100793
Open Access | Times Cited: 54
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic
Jannie Pedersen, Ismaël Hervé Koumakpayi, Giorgi Babuadze, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Rapid Induction of Long-Lasting Systemic and Mucosal Immunity via Thermostable Microneedle-Mediated Chitosan Oligosaccharide-Encapsulated DNA Nanoparticles
Minchao Li, Yang Li, Congcong Wang, et al.
ACS Nano (2023) Vol. 17, Iss. 23, pp. 24200-24217
Closed Access | Times Cited: 15
The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 5
Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs
Min Thura, Joel Sng, Koon Hwee Ang, et al.
Bioscience Reports (2021) Vol. 41, Iss. 9
Open Access | Times Cited: 39
Advanced particulate carrier-mediated technologies for nasal drug delivery
Vivek P. Chavda, Gargi Jogi, Nirav Shah, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 74, pp. 103569-103569
Closed Access | Times Cited: 26
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study
Scott Burkholz, C.v. Herst, Richard T. Carback, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 644-644
Open Access | Times Cited: 10
Factors affecting nasal drug delivery and design strategies for intranasal drug delivery
Xiao Hu, Xiao Yue, Chuanbin Wu, et al.
Journal of Zhejiang University (Medical Sciences) (2023) Vol. 52, Iss. 3, pp. 328-337
Open Access | Times Cited: 9
The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development—A Systematic Review
Marcin Goławski, Piotr Lewandowski, Iwona Jabłońska, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 991-991
Open Access | Times Cited: 14
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Dylan M. Johnson, Trevor Brasel, Shane Massey, et al.
Antiviral Research (2022) Vol. 209, pp. 105492-105492
Open Access | Times Cited: 14
A recombinant Mycobacterium smegmatis -based surface display system for developing the T cell-based COVID-19 vaccine
Ziyu Wen, Cuiting Fang, Xinglai Liu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 8
Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein
Srinivasa Reddy Bonam, Haitao Hu
Zoonoses (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 8
Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates
Marieke A. Stammes, Ji Hyun Lee, Lisette Meijer, et al.
Trends in Molecular Medicine (2021) Vol. 28, Iss. 2, pp. 123-142
Open Access | Times Cited: 19
Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
Amir Ghaemi, Parisa Roshani Asl, Hedieh Zargaran, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Virus-Induced CD8+ T-Cell Immunity and Its Exploitation to Contain the SARS-CoV-2 Pandemic
Maurizio Federico
Vaccines (2021) Vol. 9, Iss. 8, pp. 922-922
Open Access | Times Cited: 14
Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques
Alexandra C. Willcox, Kevin Sung, Meghan Garrett, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 4, pp. e1010155-e1010155
Open Access | Times Cited: 10
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease
Yvon Deschambault, Jessie Lynch, Bryce M. Warner, et al.
Journal of Virology (2022) Vol. 96, Iss. 9
Open Access | Times Cited: 9
New Vaccine Therapy for Triple-Negative Breast Cancer
Paul E. Harris, Reid Rubsamen
Current Breast Cancer Reports (2024) Vol. 16, Iss. 3, pp. 288-301
Open Access | Times Cited: 1
A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice
Yang Song, Hongqiao Hu, Kang Xiao, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 4
Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Sandra Paola Martínez-Frías, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 864-864
Open Access | Times Cited: 4
Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19
Thailin Lao, Ileanet Avalos, Elsa Rodríguez, et al.
PLoS ONE (2023) Vol. 18, Iss. 9, pp. e0288006-e0288006
Open Access | Times Cited: 2
Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top